We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Bespak | LSE:BPK | London | Ordinary Share | GB0000946276 | ORD 10P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 667.00 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
RNS Number:0477U
Bespak PLC
14 November 2005
For immediate release 14 November 2005
Bespak plc
Appointment of Dr. Peter Fellner as Non-Executive Director
Bespak plc (LSE: BPK), a leader in specialty medical devices, today announces
the appointment of Dr. Peter Fellner as a Non-Executive Director with immediate
effect.
Dr. Fellner, aged 61, is Chairman of Vernalis plc and Astex Therapeutics Ltd.
He is a Non-Executive Director of UCB SA, Qinetiq Group plc, Evotec AG and Isis
Innovation Ltd. From 1990 to 2003 he was Chief Executive of Celltech Group plc,
following which he was Chairman until 2004, when the business was acquired by
UCB.
Commenting on Dr. Fellner's appointment, John Robinson, Bespak Chairman,
commented: "We are delighted to have attracted an executive of Peter Fellner's
stature to our board. His perspectives on growing technology-led companies
organically and by acquisition will be invaluable."
For further information, please contact:
Bespak plc Tel: +44 (0) 1908 525241
Mark Throdahl - Chief Executive
Martin Hopcroft - Group Finance Director
Buchanan Communications Tel: +44 (0) 20 7466 5000
Tim Thompson / Mark Court / Mary-Jane Johnson
About Bespak plc
Bespak, a leader in specialty medical devices, is at the forefront of developing
new delivery systems for the pharmaceutical industry. The company has a product
range covering metered dose inhalers, dry powder device, actuators and
compliance aids. The company also develops and manufactures drug delivery
devices for leading global pharmaceutical companies. The group, which has
facilities in King's Lynn and Milton Keynes in the UK, is a public company
quoted on the Official List of the London Stock Exhange (LSE: BPK). For more
information, please visit www.bespak.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOADFLFFEFBBFBK
1 Year Bespak Chart |
1 Month Bespak Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
